Skip to main content
Search
Search
Advanced Search
Skip main navigation
The Evidence Base Webinar

WEBINAR: Beyond borders: The global policy forces transforming pharma pricing and market access – VIEW ON DEMAND

View On Demand
 
 
How is US policy affecting global market access, tension between global and local affiliates, and patient equity worldwide?

Navigating global versus local access is becoming increasingly complex as new US and European policies impact market entry, indication prioritization, and evidence requirements for regulatory and commercial approvals. Developments like Most-Favored Nation (MFN) agreements, the Inflation Reduction Act (IRA), and Joint Clinical Assessment (JCA) add pressure for earlier alignment of clinical and commercial evidence. Market access teams face rising challenges in adapting to these shifts. This webinar will examine the strategic effects of evolving global policies on pricing transparency, launch strategies, and patient access, and discuss the implications of a more interconnected market access environment for global healthcare and patient equity.

​Of interest to:
  • Market access and pricing professionals in pharma and biotech
  • Global strategy and policy affairs teams
  • Anyone interested in learning more about how policies in one market may impact market access in markets globally

What you will learn

  • How evolving policies, like MFN, IRA and JCA, may affect launch and access strategies at global and local levels
  • Ways to develop a globally interconnected pricing and access plan early to optimize commercial success
  • How these policies affect global health equity and patient access both within and across markets
  • Case study insights on how to successfully navigate conflicting priorities between global and local market access goals

Speakers

Jeff Henderson
Former Head of Market Access, Ironwood Pharma and Vectiv Bio

Jeff Henderson has more than 34 years of pharmaceutical and biopharmaceutical experience. He is formerly the Vice President of Global Market Access, Reimbursement, and Distribution at Ironwood Pharmaceuticals, a position he held for 5 years. Before joining Ironwood, Jeff held various executive-level market access and commercial leadership positions at various companies including Vertex Pharmaceuticals and Pfizer. He has a broad range of experience and expertise leading commercial teams within the industry and specializes in commercialization and global market access.
 
Jeff served as an officer in the United States Army for 15 years where he attained to rank of Major and is a graduate of the Virginia Military Institute with a Bachelor of Arts in History.

Tim Moore
Principal and Global BD Lead, LCP Health Analytics



Tim Moore is a Principal and Business Development Lead for the LCP Health Analytics team. With more than 35 years of global experience, Tim has worked as both a C-level pharma operator, and a strategic consulting partner across large pharma and innovative biotech. As such, he can deeply appreciate and understand the realities and challenges biopharma companies face. Thus, Tim’s role during the webinar will be to moderate the discussion to create a dialogue from the pharma operator’s perspective.

Kevin Patterson
Principal and US Access Solutions Lead, LCP Health Analytics

Kevin Patterson is one of the foremost authorities in the market access and pricing space. He has worked on pricing for more than 500 assets in the US and around the world. Originally a CPA, then hospital finance director, and CFO for CRM integrator and finally market access expert, Kevin brings a depth and breadth of business and healthcare experience to his practice.

Kevin was one of the founding partners of Medical Marketing Economics, LLC (MME) where his practice focused on specialty assets. Today, he is the lead for US Access Solution at LCP Health Analytics. Kevin has deep expertise in oncology, gene therapy, rare and orphan disease diseases, and various other specialty areas.

Kevin is a frequent advisor to the C-suite and Boards of Directors for Biopharma and the investor community.  His passion for ensuring patients access to new therapies, improving care, and health equity guides his dedication to his clients.

Dr Jasim Uddin
Principal and Market Access Lead, LCP Health Analytics
 

As a seasoned market access consultant, with over 20 years of experience in the biopharmaceutical and allied industries, Jasim has significant experience in navigating client market access challenges. He has experience of working with products across a diverse range of therapy areas and a wide range of healthcare product types, including pharmaceuticals, medical devices, diagnostics, and digital prescription therapeutics. He has a specific interest in payer value communications, particularly how to optimally translate evidence into meaningful communications and tools that aim to facilitate optimal access.

Prior to joining the LCP Health Analytics team, Jasim held senior leadership roles in other market access/HEOR consultancies, where he led multi-disciplinary teams across access, value communications, RWE, HEOR and digital solutions. In addition, he has a wealth of experience working in blue-chip pharmaceutical organizations (AstraZeneca and Novartis) across diverse roles spanning the entire product development life cycle.

Jasim holds a BSc in Pharmacology with Toxicology from King’s College London and a PhD in Investigative Medicine from Imperial College London.

In association with

If you are interested in partnering with The Evidence Base for future webinars, please contact [email protected].